SANA Stock Analysis: Buy, Sell, or Hold?
SANA - Sana Biotechnology, Inc. Common Stock
$3.14
-0.06 (-1.88%)
▼
5d:
-10.29%
30d:
-8.72%
90d:
-17.15%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Accumulation
SANA is down 10.3% this week, but smart money is accumulating calls. Top strike: $2.5 2026-07-17 with 380 OI. Call ratio: 84% View Scanner →
Strength: 8.5/10
Get Alerted When SANA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called SANA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SANA is down 10.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SANA is down 10.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SANA is currently trading at $3.14, which is considered oversold relative to its 30-day fair value range of $3.19 to $3.57.
Technical Outlook: Technically, SANA is in a strong downtrend. The price is currently testing key support at $3.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.57 (+173.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SANA is in a strong downtrend. The price is currently testing key support at $3.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.57 (+173.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.19 -
$3.57
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 173.0% below Wall St target ($8.57)
- WARNING: Recommendation downgraded due to -10.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.19 -
$3.57
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.05
Resistance Level
$3.75
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.91
Wall Street Target
$8.57
(+173.0%)
Share & Embed Analysis
Last updated: May 14, 2026 9:59 PM ET
Data refreshes hourly during market hours. Next update: 10:59 PM
Data refreshes hourly during market hours. Next update: 10:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SANA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 58 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 58 HOLD |
